Early Breast Cancer Detection With Bi-modal Molecular Imaging | 17087
Journal of Biotechnology & Biomaterials
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Breast cancer is the most frequently diagnosed cancer in women. Currently mammography is the main screening and
diagnostic tool, however it exposes the patient to radiation and its ability to distinguish benign and malignant disease
are limited which results in a large number of unnecessary biopsies. PET provides information based on a tumor?s increased
glucose consumption but doesn?t detect small tumors. Ultrasound allows differentiation between cystic and solid lesions
with sharp borders, but doesn?t provide good differentiation between malignant and benign tumors.MRI has excellent spatial
resolution but has not been applied to its full potential for the diagnosis of breast cancer due to its low specificity. At the same a
combined PET/MRI human system has been introduced to clinics. Therefore a novel contrast agent for simultaneous PET and
MR imaging that is specific to the most aggressive form of invasive ductal carcinoma (triple negative (TN)) is proposed. The
bi-modal PET and MRI contrast agent enables both PET-MRI detection of this malignant breast cancer with high sensitivity
(PET) and high spatial resolution (MRI). The development of a novel targeted contrast agent for breast molecular PET and MR
imaging will considerably increase sensitivity of these imaging technologies enabling significant improvement in diagnosis.
The specific aim of the study is to construct superparamagnetic core/shell nanoparticles that strongly reduce both T1 and T2
relaxation times. They will be conjugated with single domain antibodies (sdAbs) against three tumor targets overexpressed by
the targeted breast cancer, creating very specific and efficient contrast agents.
Barbara Blasiak completed her PhD at the Institute of Nuclear Physics, Polish Academy of Sciences, Krakow, Poland. Her PhD thesis was on molecular imaging
of glioma. Currently she is involved in applications of nano-technology in medicine at the University of Calgary, Canada. She has been a coordinator of the multi-
site, cross-Canada project on molecular imaging. She continues her work on innovative rf coils for low and high field MRI systems. Blasiak is a recipient of several
awards. She is an author of 12 publications related to molecular imaging of cancer.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals